- Home
- CBL vs OPT Comparison
CBL vs OPT Comparison
Compare CBL & OPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBL
- OPT
- Stock Information
- Founded
- CBL 1978
- OPT 1984
- Country
- CBL United States
- OPT Australia
- Employees
- CBL 469
- OPT N/A
- Industry
- CBL Real Estate Investment Trusts
- OPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CBL Real Estate
- OPT Health Care
- Exchange
- CBL Nasdaq
- OPT Nasdaq
- Market Cap
- CBL 961.6M
- OPT 855.6M
- IPO Year
- CBL 1993
- OPT 2020
- Fundamental
- Price
- CBL $31.31
- OPT $5.09
- Analyst Decision
- CBL
- OPT Strong Buy
- Analyst Count
- CBL 0
- OPT 1
- Target Price
- CBL N/A
- OPT $12.00
- AVG Volume (30 Days)
- CBL 177.2K
- OPT 42.1K
- Earning Date
- CBL 02-14-2025
- OPT 03-03-2025
- Dividend Yield
- CBL 8.96%
- OPT N/A
- EPS Growth
- CBL 999.46
- OPT N/A
- EPS
- CBL 1.87
- OPT N/A
- Revenue
- CBL $515,561,000.00
- OPT $261,859.00
- Revenue This Year
- CBL N/A
- OPT N/A
- Revenue Next Year
- CBL N/A
- OPT $46,864.26
- P/E Ratio
- CBL $17.08
- OPT N/A
- Revenue Growth
- CBL N/A
- OPT N/A
- 52 Week Low
- CBL $20.97
- OPT $1.79
- 52 Week High
- CBL $33.54
- OPT $6.30
- Technical
- Relative Strength Index (RSI)
- CBL 56.57
- OPT 53.99
- Support Level
- CBL $31.37
- OPT $4.77
- Resistance Level
- CBL $32.37
- OPT $5.46
- Average True Range (ATR)
- CBL 0.80
- OPT 0.32
- MACD
- CBL 0.11
- OPT -0.11
- Stochastic Oscillator
- CBL 38.65
- OPT 20.60
About CBL CBL & Associates Properties Inc.
CBL & Associates Properties Inc is a U.S.-based real estate investment trust. The company engages in the ownership, development, acquisition, leasing, management and operation of regional shopping malls, outlet centers, lifestyle centers, open-air centers and other properties. CBL's sales predominantly derive from leasing arrangements with retail tenants. The company also generates revenue from management and development fees, as well as sales of its real estate assets. CBL expands its portfolio of assets through activities such as redevelopment, renovation, and expansion.
About OPT Opthea Limited
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.